Navigating Virtual Tumor Boards for Prostate Cancer PSMA-PET Imaging

The panel shares their perspectives on the transition to virtual multidisciplinary tumor boards for patients with prostate cancer after the COVID-19 pandemic.

EP: 1.Risk Stratification of Patients with Prostate Cancer

EP: 2.Conventional Imaging for Prostate Cancer

EP: 3.Introduction to PSMA-Targeted PET Imaging

EP: 4.Approved PSMA-PET Imaging Tracer Options for Prostate Cancer

EP: 5.Practical Considerations for Selection of PSMA-PET Tracers

EP: 6.Impact of PSMA-Targeted Imaging Modalities on Management of Prostate Cancer

EP: 7.Overview of Available Clinical Guidelines on PSMA-PET Imaging in Prostate Cancer

EP: 8.Challenges of Implementing PSMA-Targeted PET Imaging in Prostate Cancer

EP: 9.Navigating and Overcoming Challenges of PSMA-PET Imaging Results Interpretation

EP: 10.Best Practices for Communication: A Multidisciplinary Perspective

Now Viewing

EP: 11.Navigating Virtual Tumor Boards for Prostate Cancer PSMA-PET Imaging

EP: 12.Unmet Needs in Imaging for Patients With Prostate Cancer

EP: 13.PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future

EP: 14.Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate Cancer

Related Videos

Related Content

Advertisement

July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

July 9th 2025

FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

Benjamin P. Saylor Hannah Clarke

The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

July 7th 2025

Expanded indication sought for niraparib plus AAP in Europe

Hannah Clarke

The application is supported by data from the phase 3 AMPLITUDE trial.

July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke

Take a look through all the regulatory milestones in urology from the first half of the 2025.

Related Content

Advertisement

July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

July 9th 2025

FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

Benjamin P. Saylor Hannah Clarke

The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

July 7th 2025

Expanded indication sought for niraparib plus AAP in Europe

Hannah Clarke

The application is supported by data from the phase 3 AMPLITUDE trial.

July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke

Take a look through all the regulatory milestones in urology from the first half of the 2025.